SCHEMBL10243171

SCHEMBL10243171

CCN(CCNC(=O)OC)Cc1cnc2ccccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.49
ALDH1A1 P00352 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
LMNA P02545 2/20 0.45
CYP1A2 P05177 2/20 0.45
CYP2D6 P10635 2/20 0.45
OPRK1 P41145 2/20 0.45
ABCB11 O95342 1/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45
SCN1A P35498 1/20 0.45
KCNH2 Q12809 1/20 0.45
CACNA1C Q13936 1/20 0.45
SCN5A Q14524 1/20 0.45
GHSR Q92847 1/20 0.45
SCN2A Q99250 1/20 0.45
SCN3A Q9NY46 1/20 0.45
POLB P06746 1/20 0.45
TSHR P16473 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243465 0.82 HDAC3 (0.47) KDM4EALDH1A1SMN1; SMN2OPRK1HDAC3
SCHEMBL21171736 0.80 KDM4E (0.54) KDM4EALDH1A1SMN1; SMN2LMNACYP1A2
SCHEMBL10243447 0.79 APP (0.54) KDM4EOPRK1GAAOPRM1APP
SCHEMBL21171693 0.78 ALDH1A1 (0.45) KDM4EALDH1A1SMN1; SMN2LMNACYP1A2
SCHEMBL10243109 0.75 CHRNB2 (0.48) ALDH1A1SMN1; SMN2GAAKMT2AFAAH
SCHEMBL21171886 0.75 KDM4E (0.48) KDM4EALDH1A1SMN1; SMN2LMNACYP1A2
SCHEMBL10243173 0.75 ALDH1A1 (0.44) KDM4EALDH1A1SMN1; SMN2LMNACYP1A2
SCHEMBL10243111 0.74 POLB (0.46) KDM4EALDH1A1LMNACYP1A2CYP2D6
SCHEMBL10243384 0.74 ALDH1A1 (0.49) KDM4EALDH1A1SMN1; SMN2CYP1A2CYP2D6
SCHEMBL10243147 0.73 CDYL (0.49) KDM4ECYP1A2CYP2D6MTNR1BAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 KDM4E 128/4885ALDH1A1 1939/4885SMN1; SMN2 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.